読み込み中
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
前日終値
$2.19
+$0.02 · +0.92%
日中の時刻はETです。市場データは遅延する場合があります。
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
日中レンジ
現在 $2.19
52週レンジ
現在 $2.19
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
73
割安
センチメント
58
まちまち
リスク
54
やや高いリスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
日中レンジ
現在 $2.19
52週レンジ
現在 $2.19
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1611.9万 USD | 1394.7万 USD | 1518.2万 USD | 1468.5万 USD | 639.4万 USD |
| 売上原価 | 811.3万 USD | 711.5万 USD | 1373.3万 USD | 1430.1万 USD | 676.8万 USD |
| 粗利益 | 800.6万 USD | 683.2万 USD | 144.9万 USD | 38.4万 USD | −37.4万 USD |
| 研究開発 | 4387.4万 USD | 5058.5万 USD | 4744.1万 USD | 4579.7万 USD | 2912.1万 USD |
| 販売・一般管理 | 4258.3万 USD | 5657.1万 USD | 5895万 USD | 5263万 USD | 4220.1万 USD |
| 営業費用 | 8599.8万 USD | 1.07億 USD | 1.06億 USD | 9842.7万 USD | 7132.2万 USD |
| 受取利息 | 1152.2万 USD | 1666.6万 USD | 1776.4万 USD | 460.2万 USD | 32.6万 USD |
| 支払利息 | — | — | — | — | 2.2万 USD |
| 減価償却費と償却費 | 610.4万 USD | 617.6万 USD | 557.8万 USD | 394.2万 USD | 255.8万 USD |
| 営業利益 | −7799.2万 USD | −1億 USD | −1.05億 USD | −9804.3万 USD | −7169.6万 USD |
| 純利益 | −7360万 USD | −8659.9万 USD | −8627.7万 USD | −9296.6万 USD | −7116.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI239.46万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF78万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC28.83万0.02%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM14万0.12%1.17億 USD0.73%$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC13.35万—30.82億 USD0.25%$69.98+0.03%
U.S. Micro Cap Portfolio ETFDFMC8.21万0.00%75.58億 USD0.43%$57.813+0.20%
Invesco RAFI US 1500 Small-Mid ETFPRFZ5.06万0.00%26.7億 USD0.36%$53.16+0.64%
Dimensional - US Small Cap ETFDFAS3.38万0.00%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Micro Cap Portfolio ETFDFMCInvesco RAFI US 1500 Small-Mid ETFPRFZDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
